New model aims to cure hepatitis c in homeless drug users

NCT ID NCT07667101

Recruiting now ⭐️ CURE ⭐️ Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a collaborative care model where pharmacists, doctors, and patient navigators work together to provide hepatitis C treatment to people who use drugs and live in supportive housing. 444 participants will be randomly assigned to either this model or usual care. The goal is to see if this approach increases the number of people who get evaluated and cured of hepatitis C.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Direct-acting antivirals (DAAs) for hepatitis C, plus PrEP for HIV and naloxone for overdose prevention, delivered through a pharmacist-led collaborative care model
What this could lead to: If successful, this model could cure hepatitis C in a hard-to-reach population, reducing liver disease and preventing spread of the virus.
What could go wrong: This is an implementation study, not a drug trial. Success depends on engagement and follow-up, which can be challenging in this population. The cure rate may be lower than in controlled settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS C (HCV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis C virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS C (HCV)

Contacts and locations

Locations

Harborview Medical Center
RECRUITING

Seattle, Washington, 98104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.